News

Boston Scientific, EVOLVE II, Synergy, bioresorbable stent

In the first successful United States trial of a bioabsorbable polymer stent, the Boston Scientific Synergy everolimus-eluting bioabsorbable polymer platinum chromium coronary stent system met its...

stents, Cobra, celonova

CeloNova BioSciences, Inc., announced that positive first-in-man (FIM) clinical trial results found its Cobra PzF coronary stent system with an advanced nano-thin coating of Polyzene-F polymer to...

DAPT study

Patients who took dual antiplatelet therapy medications beyond the standard 12 months after coronary stent placement were significantly less likely to develop blood clots within their stents or to...

Optimizing the treatment of coronary artery disease with a new foundation for future stent innovations, Medtronic Inc. announces CE mark and international launch of the Resolute Onyx ...

The U.S. Food and Drug Administration (FDA) has cleared the Abbott family of Xience everolimus-eluting coronary stents for the additional indication to treat coronary chronic total occlusions (...

October 20, 2014 — Boston Scientific Corp. has initiated the PLATINUM Diversity trial to evaluate the clinical performance of the Promus Premier Everolimus-Eluting Platinum...

“Once patients have survived cancer, they don't die from cancer, they die from heart disease. Cardio-oncology is about making sure that doesn't happen," said Juan Carlos Plana, M.D.

A first-of-its kind study comparing the safety and efficacy of biodegradable polymer sirolimus-eluting stents (BP-SES) to durable polymer sirolimus-eluting stents (DP-SES) found that the...

Svelte Coronary DES DIRECT II Trial Six Month Results TCT 2014

Svelte Medical Systems reported that its drug-eluting coronary stent Integrated Delivery System (IDS) for percutaneous coronary intervention (PCI) met all DIRECT II study six-month angiographic...

bioresorbable stents, dissolving stents, Absorb stent, BVS

A key prediction for interventional cardiology coming out of recent Transcatheter Cardiovascular Therapeutics (TCT) and American College of Cardiology (ACC) meetings is that bioresorbable stents...

Patient Enrollment REDUCE Sudy Combo Dual Therapy Stent OrbusNeich

OrbusNeich announced first patient enrollment in the Randomized Evaluation of short-term Dual anti platelet therapy in patients with acute coronary syndrome treated with the Combo Dual Therapy...

July 30, 2014 — OrbusNeich announced the first patient has been enrolled in the Multinational Abluminal Sirolimus Coated BiO-Engineered StenT (MASCOT) post-marketing registry. The first Combo dual...

July 15, 2014 — Micell Technologies Inc. announced the United States Patent and Trademark Office (USPTO) has issued a patent related to Micell's technology for enhancing the performance of medical...

A big fly in the ointment for widespread adoption of many new technologies is cost. In today’s cost-conscience environment of healthcare reform, there needs to be a clear, quantifiable...

OrbusNeich Patient Enrollment Completion REMEDEE Registry Combo Stent

OrbusNeich announced the completion of enrollment in the prospective, multicenter, all-comers REMEDEE Registry (Multicenter, Prospective, Clinical Outcomes After Deployment of the Abluminal...

June 10, 2014 — Ariad Pharmaceuticals Inc. and Medinol Ltd. earlier this year initiated two registration trials of Medinol’s NIRsupreme ridaforolimus-eluting coronary stent system incorporating...

Boston Scientific Promus Premier Drug Eluting Stent

Boston Scientific Corp. has launched the Promus Premier Everolimus-Eluting Platinum Chromium Coronary Stent System in Japan. This advanced drug-eluting stent (DES) technology system recently...

Biolimus Everolimus Stent Clinical Trial ACC.14

A new stent covered with biodegradable coating continues to show statistical equivalence to Japan’s market leader in cumulative second-year data and subgroup analyses, according to research from...

Medtronic Endeavor Stents Drug-eluting Antiplatelet Therapy Clinical Study

Patients with coronary artery disease who received an Endeavor or Resolute drug-eluting stent from Medtronic Inc. and subsequently interrupted their dual ...

cath lab stents drug eluting boston scientific promus premier

Boston Scientific Corporation has received U.S. Food and Drug Administration (FDA) approval for the Promus Premier Everolimus-Eluting Platinum Chromium Coronary Stent System, the company's durable...